CP-Endocrino: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
CP-Endocrino
Largest movements
- Cash +€39,436
up €39,436 (+94.7%), from €41,648 to €81,084
mainly Net result for the year (+€44,141) and Depreciation (+€7,850)
- Deferred charges and accrued income +€11,328
up €11,328 (+1,301%), from €871 to €12,199
- Tangible fixed assets -€5,161
down €5,161 (-16.3%), from €31,590 to €26,429
of which Furniture and vehicles: -€5,632
- Profit (loss) carried forward +€44,141
up €44,141 (+61.3%), from €72,019 to €116,160
- Tax, wage and social debts +€2,127
up €2,127 (+85.1%), from €2,500 to €4,627
- Gross operating margin -€16,084
down €16,084 (-20.0%), from €80,388 to €64,304
- Taxes -€3,264
down €3,264 (-21.2%), from €15,391 to €12,127
- Depreciation +€1,732
up €1,732 (+28.3%), from €6,118 to €7,850
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €77,217 | €123,313 | +€46,096 | +59.7% |
| Fixed assets | 21/28 | €31,590 | €26,429 | -€5,161 | -16.3% |
| Tangible fixed assets | 22/27 | €31,590 | €26,429 | -€5,161 | -16.3% |
| Furniture and vehicles | 24 | €29,411 | €23,779 | -€5,632 | -19.1% |
| Other tangible fixed assets | 26 | €2,179 | €2,650 | +€471 | +21.6% |
| Current assets | 29/58 | €45,627 | €96,884 | +€51,257 | +112% |
| Amounts receivable within one year | 40/41 | €3,108 | €3,601 | +€493 | +15.9% |
| Trade receivables | 40 | - | €500 | +€500 | |
| Other amounts receivable | 41 | €3,108 | €3,101 | -€7 | -0.2% |
| Cash at bank and in hand | 54/58 | €41,648 | €81,084 | +€39,436 | +94.7% |
| Deferred charges and accrued income | 490/1 | €871 | €12,199 | +€11,328 | +1,301% |
| Total equity and liabilities | 10/49 | €77,217 | €123,313 | +€46,096 | +59.7% |
| Equity | 10/15 | €74,019 | €118,160 | +€44,141 | +59.6% |
| Contributions | 10/11 | €2,000 | €2,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €72,019 | €116,160 | +€44,141 | +61.3% |
| Amounts payable | 17/49 | €3,198 | €5,153 | +€1,955 | +61.1% |
| Amounts payable within one year | 42/48 | €3,198 | €5,153 | +€1,955 | +61.1% |
| Trade debts | 44 | €299 | €526 | +€227 | +75.9% |
| Suppliers | 440/4 | €299 | €526 | +€227 | +75.9% |
| Taxes, remuneration and social security | 45 | €2,500 | €4,627 | +€2,127 | +85.1% |
| Taxes | 450/3 | €2,500 | €4,627 | +€2,127 | +85.1% |
| Other amounts payable | 47/48 | €399 | - | -€399 | |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €6,118 | €7,850 | +€1,732 | +28.3% |
| Other operating charges | 640/8 | €347 | €141 | -€206 | -59.4% |
| Gross operating margin | 9900 | €80,388 | €64,304 | -€16,084 | -20.0% |
| Operating profit (loss) | 9901 | €73,923 | €56,313 | -€17,610 | -23.8% |
| Financial income | 75/76B | €1 | - | -€1 | |
| Recurring financial income | 75 | €1 | - | -€1 | |
| Financial charges | 65/66B | €52 | €45 | -€7 | -13.5% |
| Recurring financial charges | 65 | €52 | €45 | -€7 | -13.5% |
| Profit (loss) for the period before taxes | 9903 | €73,872 | €56,268 | -€17,604 | -23.8% |
| Income taxes | 67/77 | €15,391 | €12,127 | -€3,264 | -21.2% |
| Profit (loss) for the period | 9904 | €58,481 | €44,141 | -€14,340 | -24.5% |
| Profit (loss) for the period to be appropriated | 9905 | €58,481 | €44,141 | -€14,340 | -24.5% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 24 October 2026 via checked.be.